ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 0135

Rheumatoid Arthritis Associated Risk of Venous Thromboembolism Is Not Dependent on Disease Duration: United Kingdom Based Population Study

James Galloway1, Victoria Basey2, Saqib Rana3, Simon de Lusignan4 and Maya H. Buch5, 1Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 2Pfizer UK, Tadworth, United Kingdom, 3Pfizer, Tadworth, United Kingdom, 4Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, 5Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Epidemiology, primary care, rheumatoid arthritis, risk factors

Session Information

Date: Saturday, November 16, 2024

Title: Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Risk of venous thromboembolism (VTE) is higher in patients with rheumatoid arthritis (RA) compared to the general population; however whether this risk changes with RA disease duration remains poorly understood. Acknowledging potential heterogeneity in risk by RA duration could support more tailored screening and effective preventive approaches. In a large population based study, we aimed to characterise the RA attributable VTE risk in patients with varying disease durations.

Methods: Adults registered with a general practice from January 1999 to December 2018 were identified from the Royal College of
General Practitioners Research (RCGP) and Surveillance Centre (RSC) primary care database. RA patients (diagnosed prior to and
during the study period), VTE outcome (as a composite of pulmonary embolism [PE] or deep vein thrombosis [DVT]) and individual
PE and DVT outcomes were determined using previously validated algorithms. RA unaffected controls (UCs) were matched 4:1 with
RA patients by current age, sex, calendar time, and years since practice registration using nearest neighbour matching with
replacement. Absolute VTE, PE and DVT rates over 20 years were compared in RA patients versus matched UC across 4 subgroups defined by disease duration (0-2, 2-5, 5-10 and ≥10 years since diagnosis). Across the same subgroups, relative risks over the same period were estimated using Cox proportional hazards models adjusted for sociodemographic and clinical features and established VTE risk factors (body mass index [BMI], smoking status, alcohol use, reduced mobility evidence, thrombophilia, lower limb fracture and family history of VTE).

Results: 117,050 individuals were included: 93,640 UCs and 23,410 RA patients. Of those with RA, 63.9% were included at or within 2 years of diagnosis, 7.8% within 2 to 5 years of diagnosis, 9.8% within 5 to 10 years of diagnosis, and 18.5% > 10 years after diagnosis. Average study follow up for the primary outcome (VTE) was 8.2 years (standard deviation [SD]=6.6 years). RA patients (mean age 59.0, SD 15.5; 28.9% male [n=6776]; mean BMI 27.1, SD 5.6) were similar to matched UCs in clinical characteristics. Unadjusted VTE events rates were consistently higher in RA patients compared to UCs in all subgroups. Relative risk of VTE was similarly increased in RA patients compared to the general population regardless of time since RA diagnosis (adjusted hazard ratios [aHR] range: 1.49-1.63, all p< 0.001). The results obtained when PE (aHR range 1.46-2.02, all p< 0.001) and DVT (aHR range 1.43-1.89, all p< 0.001) were analysed separately were similar to those observed in the composite outcome.

Conclusion: Healthcare professionals should recognize that RA patients face a consistently elevated VTE risk compared to the general population, irrespective of disease duration. This highlights the need for vigilant monitoring and assessment of VTE risk factors even in early stage cases.

This study was sponsored by Pfizer. Momentum Data UK provided project management, medical writing, and statistical support, funded by Pfizer.

This is an encore abstract previously presented/published for the British Society of Rheumatology Annual conference 2024 https://doi.org/10.1093/rheumatology/keae163.094


Disclosures: J. Galloway: AbbVie, 6, AstraZeneca, 5, Galapagos, 2, 6, Janssen, 2, 5, 6, Lilly, 2, 6, Pfizer, 2, 5, 6, UCB, 6; V. Basey: Pfizer, 3; S. Rana: Pfizer, 3; S. de Lusignan: AstraZeneca, 5, Eli Lilly, 5, GlaxoSmithKlein(GSK), 5, Merck/MSD, 5, Moderna, 5, Sanofi, 5, Seqirus, 5, Takeda, 5; M. Buch: AbbVie, 2, 6, Arxx Therapeutics, 2, Boehringer Ingelheim, 6, CESAS Medical, 6, Galapagos, 2, 6, Gilead, 2, 5, 6, Medistream, 6, Pfizer, 2, 6.

To cite this abstract in AMA style:

Galloway J, Basey V, Rana S, de Lusignan S, Buch M. Rheumatoid Arthritis Associated Risk of Venous Thromboembolism Is Not Dependent on Disease Duration: United Kingdom Based Population Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-associated-risk-of-venous-thromboembolism-is-not-dependent-on-disease-duration-united-kingdom-based-population-study/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-associated-risk-of-venous-thromboembolism-is-not-dependent-on-disease-duration-united-kingdom-based-population-study/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology